BRIP1 and gastric cancer: We found that the PI3K inhibitor LY294002 counteracted <i>BRIP1</i>-driven oncogenic effects, which was evidenced by restored expression of key regulators governing apoptosis, cell cycle progression, and EMT, in addition to suppressed proliferation in GC cells.